Respiratory Syncytial Virus News and Research

RSS

GenVec announces data from respiratory syncytial virus vaccine program

GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the "Keystone Symposium on Viral Immunity and Host Gene Influence", which is taking place in Keystone, Colorado from March 21-26, 2012.

26 Mar 2012

Extremely contagious RSV virus can lead to serious illness in young children

Respiratory Syncytial Virus (RSV) is a common virus that infects the lungs and breathing passage ways. Though it may only produce minor cold symptoms in adults, it can lead to serious illness in young children and those with compromised immune systems.

17 Mar 2012

Enrollment complete in Alnylam's ALN-RSV01 Phase IIb study for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed patient enrollment in its Phase IIb study with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection.

29 Nov 2011

POPG inhibits influenza infections in cell cultures and mouse models

A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity.

10 Nov 2011

RSV medication from specialty pharmacies increases likelihood of children receiving recommended doses

Children given an injectable medication to help prevent severe respiratory illness had a 17.6 percent higher likelihood of receiving the American Academy of Pediatrics (AAP) recommended doses when they were administered through a specialty pharmacy rather than a traditional pharmacy, according to a new study released today by pharmacy benefit manager Prime Therapeutics (Prime).

21 Oct 2011

MicroDose initiates MDT-637 Phase 1 trial in respiratory syncytial virus

MicroDose Therapeutx, Inc. today announced that the first human subject has been dosed in a Phase 1 clinical trial of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus.

28 Sep 2011

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

NanoBio Corporation announced today that data from recent animal studies of its NanoStat-based intranasal respiratory syncytial virus (RSV) vaccine have been published in PLoS One, an international peer-reviewed online publication.

25 Aug 2011

Kineta's next generation antiviral program receives $2.8 million NIH SBIR grant

Kineta, Inc. announced today its next generation antiviral program has received a 2.8 million dollar grant from the National Institute of Allergy and Infectious Disease, a part of the National Institutes of Health (NIH). Awarded under the Small Business Innovation Research (SBIR) program, the prestigious phase two grant will provide on-going support for Kineta's work on a new class of antiviral drugs targeting an array of global, deadly viruses.

12 Aug 2011

Study finds very low rates of pertussis in children with cough

Contrary to some recent studies, only a low percentage of children treated for respiratory illness with cough have unsuspected pertussis, reports a study in the August issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

10 Aug 2011

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

NanoBio Corporation today announced a licensing agreement with the National Institutes of Health (NIH) that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.

4 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

Serious RSV infections may occur in previously healthy infants and children

For most parents, respiratory syncytial virus (RSV) isn't a familiar term. But it's a common cause of serious respiratory infections with a major impact on the health of infants and young children worldwide, according to a special CDC Review Article in the June issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Jun 2011

Novavax first quarter net loss decreases to $7.5 million

Novavax, Inc. today announced its financial results for the first quarter ended March 31, 2011.

9 May 2011

Quest Diagnostics' Simplexa C. difficile test is now available in Europe

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced the availability in Europe of the Simplexa C. difficile Universal Direct test on the 3M Integrated Cycler.

From Quest Diagnostics 6 May 2011

FDA clears ITI's FilmArray RP assay for respiratory virus detection

Idaho Technology, Inc. announced today that the U.S. Food and Drug Administration has issued a 510(k) clearance for the FilmArray instrument and the FilmArray Respiratory Panel.

3 May 2011

MedImmune abstracts on influenza and RSV to be presented at PAS meeting

MedImmune announced today it will present 11 abstracts at the Pediatric Academic Societies Meeting at the Colorado Convention Center in Denver, CO, April 30 - May 3, 2011.

2 May 2011

Gilead, MicroDose enter collaboration for inhalable small molecule antiviral fusion inhibitor MDT-637

Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).

20 Apr 2011

Quest Diagnostics Simplexa molecular test receives bronze award for best new product

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa™ molecular test on the 3M™ Integrated Cycler was honored with a bronze award for best new science and medical diagnostic product during the 2011 Edison Awards gala ceremony last night in New York City.

From Quest Diagnostics 7 Apr 2011

New discovery in childhood respiratory disease

Researchers have identified a critical part of the process by which one of the world's most common and dangerous early childhood infections, respiratory syncytial virus, causes disease.

8 Mar 2011

February is again peak time for influenza across the nation

If you thought the regular seasonal flu has been late making its annual appearance, you might be surprised to learn that based on recent history, it's right on time.

15 Feb 2011